Rivoglitazone

Rivoglitazone

Clinical data
ATC code	none
Identifiers
IUPAC name (RS)-5-{4-[(6-methoxy-1-methyl-1H-benzimidazol-2-yl) methoxy]benzyl}-1,3-thiazolidine-2,4-dione
CAS Number	185428-18-6
PubChem (CID)	3055168
ChemSpider	2316729
UNII	3A3N0634Q6
ChEMBL	CHEMBL2104753
Chemical and physical data
Formula	C20H19N3O4S
Molar mass	397.448 g/mol
3D model (Jmol)	Interactive image
SMILES CN1C2=C(C=CC(=C2)OC)N=C1COC3=CC=C(C=C3)CC4C(=O)NC(=O)S4
InChI InChI=1S/C20H19N3O4S/c1-23-16-10-14(26-2)7-8-15(16)21-18(23)11-27-13-5-3-12(4-6-13)9-17-19(24)22-20(25)28-17/h3-8,10,17H,9,11H2,1-2H3,(H,22,24,25) Key:XMSXOLDPMGMWTH-UHFFFAOYSA-N
(verify)

Rivoglitazone (INN) is a thiazolidinedione derivative undergoing research for use in the treatment of type 2 diabetes.^[1][2]

It is being developed by Daiichi Sankyo.

References

1. Schimke K; Davis ™ (2007). "Drug evaluation: rivoglitazone, a new oral therapy for the treatment of type 2 diabetes". Curr Opin Investig Drugs. 8 (4): 338–44. PMID 17458185.
2. Kong AP, Yamasaki A, Ozaki R, Saito H, Asami T, Ohwada S, Ko GT, Wong CK, Leung GT, Lee KF, Yeung CY, Chan JC (2011). "A randomized-controlled trial to investigate the effects of rivoglitazone, a novel PPAR gamma agonist on glucose-lipid control in type 2 diabetes". Diabetes Obes Metab. 13 (9): 806–13. doi:10.1111/j.1463-1326.2011.01411.x. PMID 21492364.